# Iksuda Therapeutics

Source: https://onco.cc/companies/iksuda-therapeutics/  
OnCo record `iksuda-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Iksuda Therapeutics, based in Newcastle, designs antibody-drug conjugates, antibodies that release a cancer-killing drug only once inside the tumour. Its HER2-targeting medicine is in early human trials, with encouraging results in oesophageal cancer.

## Summary

Iksuda Therapeutics develops antibody-drug conjugates built around tumour-selective release and activation of payloads, combining stable conjugation (its PermaLink platform) with prodrug payloads including its proprietary protein-alkylating ProAlk class. The lead asset IKS014 is a HER2-directed ADC in a phase 1 study in HER2-positive and HER2-low solid tumours; ESMO 2025 dose-escalation data showed anti-tumour activity across dose levels, and a preliminary analysis at the 2026 ASCO GI symposium reported an 80 percent clinical benefit rate in 10 previously treated patients with HER2-positive oesophageal cancer. IKS03 is a CD19-targeted ADC for B-cell malignancies, and IKS04, a CA242 (CanAg)-directed pyrrolobenzodiazepine ADC given with unconjugated antibody, received FDA IND clearance in July 2026 for phase 1 trials in gastrointestinal cancers. The company closed a USD 47 million financing in June 2021 co-led by Mirae Asset Capital and Celltrion.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: Newcastle upon Tyne
- Type: biotech
- Website: https://www.iksuda.com/

## Notes

- Later financing (reported elsewhere in 2023) not found on the company news pages fetched. Founding year not sourced.

## Sources

- Official website: https://www.iksuda.com/
- USD 47 million financing release: https://www.iksuda.com/news-views/iksuda-therapeutics-closes-47-million-financing-round/
- News and views: https://www.iksuda.com/news-views/

## Connected records

- cancers: [Oesophageal cancer](https://onco.cc/cancers/esophageal/)
- fronts: [Antibody-Drug Conjugates](https://onco.cc/fronts/adcs/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- targets: [CD19](https://onco.cc/targets/cd19/), [HER2](https://onco.cc/targets/her2/)

---
JSON: https://onco.cc/api/v1/entities/iksuda-therapeutics.json